Effectiveness of Laparoscopic Sleeve Gastrectomy in Treating Obesity and Its Co-morbidities.
10.3881/j.issn.1000-503X.10717
- Author:
Zi Jian LI
1
;
Jian Chun YU
1
;
Wei Ming KANG
1
;
Zhi Qiang MA
1
;
Xin YE
1
;
Hui Juan ZHU
2
;
Kang YU
3
;
Wei CHEN
3
;
Yan Ping LIU
3
;
Tao LI
4
;
Yi XIAO
5
;
Jin Mei LUO
5
;
Shu Yang ZHANG
6
Author Information
1. Department of General Surgery, CAMS and PUMC,Beijing 100730,China.
2. Department of Endocrinology, CAMS and PUMC,Beijing 100730,China.
3. Department of Nutrition, CAMS and PUMC,Beijing 100730,China.
4. Department of Psychology, CAMS and PUMC,Beijing 100730,China.
5. Department of Respiratory Medicine, CAMS and PUMC,Beijing 100730,China.
6. Department of Cardiology,PUMC Hospital, CAMS and PUMC,Beijing 100730,China.
- Publication Type:Journal Article
- From:
Acta Academiae Medicinae Sinicae
2018;40(5):610-616
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the effectiveness and safety of laparoscopic sleeve gastrectomy (LSG) in treating obesity and its co-morbidities.Methods The clinical data of obese patients undergoing LSG in Peking Union Medical College Hospital from August 2012 to August 2017 were retrospectively analyzed. Medium-term outcome measures included excess weight loss (%EWL),co-morbidity improvement,and complications.Results Seventy-five obese patients comprising 28 men[ body mass index(BMI):(47.3±7.5)kg/m ) ] and 47 women [BMI (41.1±7.0) kg/m ] were enrolled in this analysis. The common co-morbidities were liver dysfunction (53.3%),dyslipidemia (52.0%),obstructive sleep apnea (45.3%),type 2 diabetes mellitus (38.7%),and arterial hypertension (37.3%),which were improved by 75.0%,58.3%,83.3%,75.0% and 58.3% three years after surgery. The mean %EWL at 1,2,and 3 years after surgery was 81.6±34.7,80.9±30.2 and 79.7±30.8,respectively. The proportions of patients achieving successful weight loss were 81.7% (n=49),81.0% (n=34),and 79.3% (n=23) at 1,2,and 3 years (%EWL>50%). Early severe complications (Clavien-Dindo classification>2) occurred in 2.6% of patients,and the most common late complications was gastroesophageal reflux disease,which could be relieved by acid suppressants.Conclusion LSG is effective and safe in treating obesity and its co-morbidities.
